O	0	6	Effect
O	7	9	of
O	10	16	adding
B-intervention	17	26	gefitinib
O	27	29	to
O	30	41	neoadjuvant
O	42	54	chemotherapy
O	55	57	in
O	58	66	estrogen
O	67	75	receptor
O	76	84	negative
O	85	90	early
O	91	97	breast
O	98	104	cancer
O	105	107	in
O	108	109	a
O	110	120	randomized
O	121	126	phase
O	127	129	II
O	130	135	trial
O	135	136	.

O	137	146	Gefitinib
O	146	147	,
O	148	150	an
O	151	160	epidermal
O	161	167	growth
O	168	174	factor
O	175	183	receptor
O	184	192	tyrosine
O	193	199	kinase
O	200	209	inhibitor
O	209	210	,
O	211	214	has
O	215	220	shown
O	221	225	both
O	226	230	anti
O	230	231	-
O	231	244	proliferative
O	245	248	and
O	249	253	anti
O	253	254	-
O	254	261	tumoral
O	262	270	activity
O	271	273	in
O	274	280	breast
O	281	287	cancer
O	287	288	.

O	289	293	This
O	294	299	study
O	300	303	was
O	304	312	designed
O	313	315	to
O	316	325	determine
O	326	329	the
O	330	336	effect
O	337	339	of
O	340	346	adding
O	347	356	gefitinib
O	357	359	to
O	360	371	neoadjuvant
O	372	382	epirubicin
O	383	386	and
O	387	403	cyclophosphamide
O	404	405	(
O	405	407	EC
O	407	408	)
O	409	411	on
O	412	417	tumor
O	418	426	response
O	427	432	rates
O	432	433	.

B-eligibility	434	439	Women
I-eligibility	440	444	with
I-eligibility	445	455	unilateral
I-eligibility	455	456	,
I-eligibility	457	464	primary
I-eligibility	465	473	operable
I-eligibility	473	474	,
I-eligibility	475	483	estrogen
I-eligibility	484	492	receptor
I-eligibility	493	501	negative
I-eligibility	502	510	invasive
I-eligibility	511	517	breast
I-eligibility	518	524	cancer
I-eligibility	525	526	â‰¥
I-eligibility	527	528	2
I-eligibility	529	531	cm
O	532	536	were
O	537	545	eligible
O	546	549	for
O	550	559	inclusion
O	559	560	.

O	561	571	Randomized
O	572	580	patients
O	581	585	were
O	586	588	to
O	589	596	receive
O	597	601	four
O	602	608	cycles
O	609	611	of
O	612	623	neoadjuvant
O	624	626	EC
O	627	631	plus
O	632	634	12
O	635	640	weeks
O	641	643	of
O	644	650	either
O	651	660	gefitinib
O	661	662	(
O	662	665	250
O	666	668	mg
O	669	674	daily
O	674	675	)
O	676	678	or
B-control	679	686	placebo
O	686	687	.

O	688	695	Primary
O	696	704	endpoint
O	705	708	was
B-outcome-Measure	709	719	pathologic
I-outcome-Measure	720	728	complete
I-outcome-Measure	729	737	response
I-outcome-Measure	738	739	(
I-outcome-Measure	739	742	pCR
I-outcome-Measure	742	743	)
O	743	744	,
O	745	748	and
O	749	758	secondary
O	759	768	endpoints
O	769	773	were
B-outcome-Measure	774	782	complete
I-outcome-Measure	783	791	response
I-outcome-Measure	792	793	(
I-outcome-Measure	793	795	CR
I-outcome-Measure	795	796	)
O	797	800	and
B-outcome-Measure	801	808	overall
I-outcome-Measure	809	818	objective
I-outcome-Measure	819	827	response
I-outcome-Measure	828	829	(
I-outcome-Measure	829	831	OR
I-outcome-Measure	831	832	)
O	832	833	.

B-total-participants	834	837	181
O	838	846	patients
O	847	851	were
O	852	862	randomized
O	862	863	.

O	864	865	A
B-outcome	866	869	pCR
O	870	873	was
O	874	882	observed
O	883	885	in
B-iv-bin-percent	886	888	17
I-iv-bin-percent	888	889	%
O	890	891	(
B-iv-bin-abs	891	893	12
O	893	894	/
B-intervention-participants	894	896	71
O	896	897	)
O	898	900	of
O	901	909	patients
O	910	917	treated
O	918	922	with
O	923	932	gefitinib
O	933	936	and
O	937	939	in
B-cv-bin-percent	940	942	12
I-cv-bin-percent	942	943	%
O	944	945	(
B-cv-bin-abs	945	946	9
O	946	947	/
B-control-participants	947	949	73
O	949	950	)
O	951	953	of
O	954	962	patients
O	963	970	treated
O	971	975	with
O	976	983	placebo
O	984	985	(
O	985	986	4
O	986	987	.
O	987	989	57
O	989	990	%
O	991	1001	difference
O	1001	1002	,
O	1003	1005	95
O	1005	1006	%
O	1007	1009	CI
O	1010	1011	-
O	1011	1012	7
O	1012	1013	.
O	1013	1015	19
O	1016	1018	to
O	1019	1020	6
O	1020	1021	.
O	1021	1023	33
O	1023	1024	;
O	1025	1026	P
O	1027	1028	=
O	1029	1030	0
O	1030	1031	.
O	1031	1033	44
O	1033	1034	)
O	1034	1035	.

B-outcome	1036	1038	CR
O	1039	1042	was
O	1043	1051	observed
O	1052	1054	in
B-iv-bin-percent	1055	1057	10
I-iv-bin-percent	1057	1058	%
O	1059	1061	of
O	1062	1070	patients
O	1071	1073	in
O	1074	1078	both
O	1079	1082	the
O	1083	1092	gefitinib
O	1093	1094	(
B-iv-bin-abs	1094	1095	7
O	1095	1096	/
B-intervention-participants	1096	1098	71
O	1098	1099	)
O	1100	1103	and
O	1104	1107	the
O	1108	1115	placebo
O	1116	1121	group
O	1122	1123	(
B-cv-bin-abs	1123	1124	7
O	1124	1125	/
B-control-participants	1125	1127	73
O	1127	1128	)
O	1129	1130	(
O	1130	1131	0
O	1131	1132	.
O	1132	1134	27
O	1134	1135	%
O	1136	1146	difference
O	1146	1147	,
O	1148	1150	95
O	1150	1151	%
O	1152	1154	CI
O	1155	1156	-
O	1156	1157	9
O	1157	1158	.
O	1158	1159	6
O	1160	1162	to
O	1163	1165	10
O	1165	1166	.
O	1166	1167	2
O	1167	1168	;
O	1169	1170	P
O	1171	1172	=
O	1173	1174	0
O	1174	1175	.
O	1175	1177	96
O	1177	1178	)
O	1178	1179	.

O	1180	1185	There
O	1186	1189	was
O	1190	1192	no
O	1193	1204	significant
O	1205	1215	difference
O	1216	1218	in
B-outcome	1219	1221	OR
O	1222	1223	(
O	1223	1224	5
O	1224	1225	.
O	1225	1227	96
O	1227	1228	%
O	1228	1229	;
O	1230	1232	95
O	1232	1233	%
O	1234	1236	CI
O	1237	1238	-
O	1238	1239	9
O	1239	1240	.
O	1240	1241	9
O	1242	1244	to
O	1245	1247	21
O	1247	1248	.
O	1248	1249	9
O	1249	1250	;
O	1251	1252	P
O	1253	1254	=
O	1255	1256	0
O	1256	1257	.
O	1257	1259	45
O	1259	1260	)
O	1261	1268	between
O	1269	1272	the
O	1273	1276	two
O	1277	1283	groups
O	1283	1284	.

O	1285	1289	Post
O	1290	1293	hoc
O	1294	1302	subgroup
O	1303	1311	analysis
O	1312	1318	showed
O	1319	1320	a
O	1321	1332	significant
O	1333	1343	difference
O	1344	1346	in
O	1347	1350	pCR
O	1351	1358	between
O	1359	1365	triple
O	1366	1374	negative
O	1375	1381	breast
O	1382	1388	cancer
O	1389	1390	(
O	1390	1394	TNBC
O	1394	1395	)
O	1396	1399	and
O	1400	1403	non
O	1403	1404	-
O	1404	1408	TNBC
O	1409	1415	tumors
O	1416	1417	(
O	1417	1418	P
O	1419	1420	=
O	1421	1422	0
O	1422	1423	.
O	1423	1425	03
O	1425	1426	)
O	1426	1427	.

O	1428	1432	More
O	1433	1441	patients
O	1442	1444	in
O	1445	1448	the
O	1449	1458	gefitinib
O	1459	1462	arm
O	1463	1466	had
B-outcome	1467	1480	hematological
I-outcome	1481	1489	toxicity
O	1490	1491	(
O	1491	1492	P
O	1493	1494	=
O	1495	1496	0
O	1496	1497	.
O	1497	1499	15
O	1499	1500	)
O	1501	1504	and
B-outcome	1505	1517	discontinued
I-outcome	1518	1527	treatment
O	1528	1529	(
B-iv-bin-abs	1529	1530	9
O	1530	1531	/
B-intervention-participants	1531	1533	94
O	1534	1536	vs
O	1536	1537	.
B-cv-bin-abs	1538	1539	2
O	1539	1540	/
B-control-participants	1540	1542	86
O	1542	1543	)
O	1544	1551	because
O	1552	1554	of
O	1555	1562	adverse
O	1563	1569	events
O	1570	1571	(
O	1571	1573	AE
O	1573	1574	)
O	1574	1575	.

B-outcome	1576	1581	Tumor
I-outcome	1582	1590	response
I-outcome	1591	1596	rates
O	1597	1601	were
O	1602	1609	similar
O	1610	1612	in
O	1613	1616	the
O	1617	1620	two
O	1621	1627	groups
O	1627	1628	.

O	1629	1630	A
O	1631	1644	significantly
O	1645	1651	higher
B-outcome	1652	1655	pCR
I-outcome	1656	1660	rate
O	1661	1664	was
O	1665	1673	observed
O	1674	1678	post
O	1679	1682	hoc
O	1683	1685	in
O	1686	1690	TNBC
O	1691	1697	versus
O	1698	1701	non
O	1701	1702	-
O	1702	1706	TNBC
O	1707	1718	independent
O	1719	1721	of
O	1722	1731	treatment
O	1731	1732	.

O	1733	1737	More
O	1738	1746	patients
O	1747	1749	in
O	1750	1753	the
O	1754	1763	gefitinib
O	1764	1769	group
B-outcome	1770	1782	discontinued
I-outcome	1783	1792	treatment
O	1793	1800	because
O	1801	1803	of
O	1804	1806	AE
O	1806	1807	.
